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oversuppression, and calcium-containing 
binders should be avoided in patients with 
such a condition.11
In summary, vascular calcifications are 
associated with increased mortality in dial-
ysis patients. Different methods can be used 
to identify vascular calcifications in these 
patients. Plain X-ray evaluation of vascular 
calcifications is inexpensive and simple to 
interpret and should be used for the screen-
ing of vascular calcifications. Nephrologists 
have now at their disposal different plain 
X-ray methods to evaluate vascular calcifi-
cations in their CKD patients. The presence 
of vascular calcifications in CKD patients 
constitutes an important alert sign for an 
increased cardiovascular risk. This infor-
mation is important and should serve to 
guide nephrologists in the design of more 
appropriate and aggressive therapeutic 
strategies to control mineral metabolism 
in their patients.
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DRIVE it home:  
making the case for prospective 
economic data collection  
in randomized clinical trials
Eric L. Eisenstein1
Although the results of Pizzi et al. point to the potential economic 
attractiveness of a ferric gluconate treatment strategy, they may not be 
sufficient to change public policy and reimbursement practices. What is 
required is a large, simple trial that will replicate the results of the DRIVE trial 
in a broader population with longer follow-up and a prospectively defined 
economic and quality-of-life study conducted from the societal perspective.
Kidney International (2008) 74, 1507–1509. doi:10.1038/ki.2008.553 
In 1972, Archie Cochrane put forth three 
tests that all medical technologies must 
pass.1 The first test, of efficacy, assesses 
whether the new technology can work 
under ideal circumstances, such as those 
found in a randomized clinical trial. The 
second test, of effectiveness, evaluates 
whether the technology works under usual 
circumstances, such as those found in actual 
practice. And the third test, of efficiency, 
determines whether the new technology is 
worth it—put differently, whether there is 
a proper relationship between the benefits 
derived through the use of the technol-
ogy and the resources it consumes (Figure 
1). While the renal research community 
has demonstrated increasing success in 
answering Cochrane’s first two questions 
with respect to important clinical and pol-
icy issues, it has exhibited less interest in his 
third question. In few areas is the disparity 
between clinical and economic research 
greater than in the appropriate use of epo-
etin alfa for anemia correction in patients 
with kidney disease.
In recent years, our understanding of 
the efficacy and effectiveness of epoetin 
alfa in patients with kidney disease has 
increased substantially. The Cardiovascu-
lar Risk Reduction by Early Anemia Treat-
ment with Epoetin Beta (CREATE) study 
reported that complete correction of ane-
mia in patients with chronic kidney disease 
does not reduce the risk of cardiovascular 
events.2 This message was amplified by the 
Correction of Hemoglobin and Outcomes 
in Renal Insufficiency (CHOIR) study, 
which reported that the use of higher ver-
sus lower target hemoglobin levels is asso-
ciated with increased cardiovascular risk 
with no improvement in quality of life.3 
Subsequently, a secondary analysis from the 
CHOIR study refocused the discussion by 
reporting that patients who achieved their 
hemoglobin targets (whether lower- or 
higher-level) had better cardiovascular out-
comes than those who did not.4 The under-
lying issue was that a greater proportion of 
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patients randomized to a higher versus 
lower hemoglobin level failed to achieve 
target and required higher doses of epoetin 
alfa. The Dialysis Patients’ Response to IV 
Iron with Elevated Ferritin (DRIVE) trial 
and its observational extension (DRIVE-II) 
further extended the discussion.5,6 DRIVE 
evaluated the efficacy of intravenous ferric 
gluconate in anemic hemodialysis patients 
with high ferritin and low transferrin satu-
ration.5 This study found that the admin-
istration of ferric gluconate in patients 
receiving an adequate dose of epoetin alfa 
was associated with increased hemoglobin 
at 6 weeks. The DRIVE-II study found that 
when adjustments to epoetin and intrave-
nous iron doses were allowed, the required 
epoetin dose decreased among patients 
randomized to ferric gluconate, whereas it 
did not change in the controls.6 Over the 
combined 12-week follow-up period for 
these studies, patients in the ferric gluconate 
group experienced fewer serious adverse 
events than controls, largely because of dif-
ferences in cardiac and infection events.
Pizzi and colleagues7 (this issue) per-
formed a retrospective economic analy-
sis using results from the DRIVE studies 
and report that the use of ferric gluconate 
versus control was associated with a sig-
nificant reduction in medical costs during 
the 12-week study period. While we are all 
familiar with the typical cost-effectiveness 
analysis that involves trade-offs between 
the incremental benefits and incremental 
medical costs associated with a new ther-
apy versus the standard of care, and we can 
imagine situations in which a newer therapy 
(for example, a generic) may have the same 
effectiveness as its alternative (for example, 
a brand name) but may be offered at a lesser 
price, we rarely find situations in which a 
newer therapy both is more effective and 
costs less than the standard of care. The 
results in this study prompt two questions: 
(1) have the authors properly answered 
Cochrane’s third question; and (2) how 
should these results impact health policy 
and reimbursement decisions? Put differ-
ently: do we believe it, and if so, what should 
we do? Both of these questions relate to our 
perceptions of the validity of this analysis.
Beginning in the mid-1990s, several 
standards have been proposed for the 
conduct and reporting of health economic 
analyses, including those commissioned 
by the United States and British govern-
ments.8,9 Although the content of each 
standard differs in certain aspects from the 
others, they all contain a set of common 
elements that can be used to answer 
Cochrane’s efficiency question. These 
include the measurement of health benefits 
(clinical outcomes and the values we attach 
to them) and medical costs (use of medi-
cal resources and their unit prices), along 
with a set of factors that serve to determine 
the economic context for the analysis. Con-
text factors include the description of the 
interventions and the intervention setting, 
characteristics of the study population, 
determination of cost-generating events, 
analysis perspective, time horizon, and 
scale of the investment required. Following 
these standards provides a degree of face 
validity for an economic analysis.
As Pizzi et al.7 recognize, the DRIVE 
economic analysis was limited in its meth-
ods, because the DRIVE studies were not 
designed to prospectively collect economic 
and quality-of-life data. Thus, they had to 
rely on clinical data supplemented with 
economic inputs from other sources. This 
design necessarily omitted key cost ele-
ments (such as physician fees and the costs 
of dialysis sessions) and was not able to cap-
ture the variability inherent in hospitaliza-
tion costs. The selection of a decision model 
with probabilistic sensitivity analysis was 
an attempt to correct this problem; how-
ever, its use may have overestimated the 
actual variability. A better method would 
have been to compute costs at the patient 
level and use a non-parametric bootstrap 
to estimate mean cost differences between 
treatment strategies with 95% confidence 
intervals.10 The absence of quality-of-life 
data may perhaps be the greatest data-col-
lection omission in DRIVE. Since increase 
in hemoglobin was the primary end point, 
a robust quality-of-life analysis may have 
served to put the clinical and economic 
results in perspective. As it is, we know that 
hemoglobin is increased and medical costs 
are decreased; however, we do not know 
whether the reduction in epoetin alfa use is 
associated with changes in quality of life.
The DRIVE studies are of interest from 
an economic perspective in that the pri-
mary clinical benefit (increase in hemo-
globin) associated with ferric gluconate 
versus control occurs largely during the 
first phase, whereas the economic benefits 
(reduced epoetin alfa use, and reduced 
adverse events) occur during the second 
phase. Since both the clinical and the 
economic benefits were evident within a 
relatively short time frame, one wonders 
what would have happened had the follow-
up period extended beyond 12 weeks. Since 
the late benefits were largely economic, it 
is quite possible that the analysis of Pizzi et 
al.7 underestimates the true economic ben-
efits to be derived from the ferric gluconate 
treatment strategy. If this is the case, the 
hypothesized benefits to Medicare through 
the widespread adoption of this treatment 
strategy are also underestimated.
Limitations in economic data collection 
also necessitated that the analysis be per-
formed only from the payer’s perspective. 
In contrast, a primary economic analy-
sis from the societal perspective would 
have evaluated the health benefits versus 
Figure 1 | Economic attractiveness: balancing costs and benefits.
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medical costs that might accrue to soci-
ety through implementation of the ferric 
gluconate treatment strategy. After this 
analysis was completed, secondary analyses 
could perform evaluations from the payer 
and provider perspectives. The use of alter-
native perspectives is important because, 
while the use of a new therapy versus 
standard of care may be good for society, 
its implementation frequently depends 
on its making economic sense from key 
secondary perspectives. In this instance, it 
appears that payers will gain through lower 
reimbursements for anemia therapies and 
patient hospitalizations, while dialysis 
facilities will lose revenues from reduced 
epoetin alfa use. Thus, economic incen-
tives may be required to encourage dialysis 
facilities to adopt the ferric gluconate treat-
ment strategy.
In 2003, the Centers for Medicare & 
Medicaid Services (CMS) created two 
new Diagnosis Related Groups to cover 
the expected costs associated with drug-
eluting stents. While these groups were cre-
ated before Food and Drug Administration 
approval of the first drug-eluting stent, they 
were based on clinical trial results demon-
strating reductions in repeat revasculari-
zation procedures. In this situation, CMS 
was creating a financial mechanism that 
would allow hospitals to use a viable new 
technology without being financially disad-
vantaged. Perhaps a similar incentive could 
be used in the present situation.
Clearly, the results of Pizzi and col-
leagues7 point to the potential economic 
attractiveness of a ferric gluconate treat-
ment strategy. While these results serve to 
frame Cochrane’s efficiency question and 
are credible, they may not be sufficient 
of themselves to change public policy 
and reimbursement practices. What is 
required is a large, simple trial that will 
replicate the DRIVE results in a broader 
population with longer follow-up and a 
prospectively defined economic and qual-
ity-of-life study conducted from the soci-
etal perspective. Such a trial would both 
address the public policy and reimburse-
ment questions and serve as a model for 
how to incorporate prospective economic 
data collection into randomized clinical 
trials of kidney disease patients.
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First responders: understanding 
monocyte-lineage traffic in the 
acutely injured kidney
Sundararaman Swaminathan1 and Matthew D. Griffin2
Interstitial monocytic infiltration of the kidney occurs within hours of 
acute kidney injury and is an important determinant of functional decline 
and fibrosis. Li et al. used several surface markers to distinguish between 
dendritic cells and inflammatory monocytes following acute kidney injury 
and to identify two chemokine receptors that regulate monocyte traffic. This 
Commentary examines the degree to which monocyte-lineage diversity, 
trafficking, and contribution to renal injury have been teased out to date.
Kidney International (2008) 74, 1509–1511. doi:10.1038/ki.2008.555
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Bone marrow-derived cells play a central 
part in the acute response of the kidney 
to ischemia–reperfusion (IR) and other 
forms of injury. In the hours and days 
following IR, conventional histology 
readily indicates the increased presence 
of polymorphonuclear leukocytes, lym-
phocytes, and monocytes in the renal 
interstitial spaces. Furthermore, a variety 
of experimental approaches confirm that 
such infiltrating cells participate both 
in the harmful processes (widespread 
apoptosis, increased interstitial fibro-
sis, loss of peritubular capillaries) that 
compromise renal function and in the 
healing phase of injury.1 Thus, strategies 
to manipulate the traffic and function of 
bone marrow-derived cells represent a 
promising direction for translational 
research in acute kidney injury (AKI). 
Surprisingly, however, while progress 
in the field of immunology has revealed 
